🟢 Strong Evidence
The European Medicines Agency has withdrawn all levamisole-containing medicines from EU markets following identification of serious neurological complications, according to Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC). The Italian Medicines Agency (AIFA) endorsed the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) recommendation on 6 April 2026.
Key takeaways
- EMA’s safety committee recommends complete withdrawal of levamisole medicines from EU market
- Decision follows identification of serious neurological adverse effects in patients
- Nigerian drug regulator NAFDAC alerts healthcare providers and patients about the safety concerns
Regulatory Timeline: Levamisole Withdrawal Process
Key dates in European drug safety action, 2026
Source: NAFDAC Public Alert, 2026 | Georgian Medical Journal News
Safety Committee Identifies Neurological Risks
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee identified serious neurological adverse effects associated with levamisole use, prompting the withdrawal recommendation. According to the EMA’s pharmacovigilance framework, such recommendations undergo rigorous scientific evaluation before implementation.
Levamisole, historically used as an antiparasitic agent, has been associated with various safety concerns in clinical practice. The drug’s mechanism of action involves immune system modulation, which may contribute to its neurological side effect profile.
Regulatory Response Across Jurisdictions
Nigeria’s NAFDAC issued Public Alert No. 030/2026 following notification of the European regulatory action. The agency routinely monitors international drug safety alerts to inform domestic healthcare stakeholders about emerging risks.
The Italian Medicines Agency’s endorsement reflects the EU’s coordinated approach to drug safety, where member state regulators implement PRAC recommendations through their national frameworks. This system ensures rapid implementation of safety measures across the European market.
The Pharmacovigilance Risk Assessment Committee recommended complete withdrawal of levamisole-containing medicines following identification of serious neurological complications
— European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC recommendation, April 2026)
Clinical Implications for Healthcare Providers
Healthcare providers should immediately review patient treatment protocols involving levamisole-containing medicines. The withdrawal affects all formulations and indications previously approved in European markets.
Alternative therapeutic options should be considered for patients currently receiving levamisole treatment. The WHO’s guidelines on rational drug use emphasize the importance of risk-benefit assessment in therapeutic substitution decisions.
What this means
Frequently asked questions
What neurological risks are associated with levamisole?
The EMA’s safety committee identified serious neurological adverse effects, though specific symptoms were not detailed in the public alert. Patients should monitor for any new or worsening neurological symptoms.
Which medicines contain levamisole?
The withdrawal affects all levamisole-containing medicines previously approved in EU markets. Patients should check medication labels and consult healthcare providers for identification.
How quickly should patients stop taking levamisole?
Patients should consult their healthcare providers immediately about discontinuation protocols. Abrupt cessation may not be appropriate for all clinical situations without proper medical supervision.
This regulatory action demonstrates the effectiveness of international pharmacovigilance cooperation in identifying and responding to emerging drug safety signals. The coordinated response between European regulators and global health authorities like NAFDAC ensures broad dissemination of critical safety information to protect patient welfare across diverse healthcare systems.
Source: Public Alert No. 030/2026: Alert on the Withdrawal of Levamisole-Containing Medicines
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
